Published in Clin Pharmacol Ther on August 01, 2000
Fenofibrate Intervention as COVID-19 Therapy (FERMIN) | NCT04517396
Impact of OATP transporters on pharmacokinetics. Br J Pharmacol (2009) 2.97
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Use of fibrates in the United States and Canada. JAMA (2011) 2.82
Successful strategy to improve the specificity of electronic statin-drug interaction alerts. Eur J Clin Pharmacol (2009) 1.14
Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther (2014) 1.10
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol (2012) 1.10
Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol (2003) 0.98
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol (2012) 0.98
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol (2005) 0.88
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br J Clin Pharmacol (2005) 0.88
Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach. Clin Pharmacol Ther (2015) 0.87
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol (2004) 0.87
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab (2011) 0.86
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol (2006) 0.82
Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag (2005) 0.82
Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. Int J Nanomedicine (2006) 0.82
Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. Drug Metabol Drug Interact (2014) 0.82
Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol (2006) 0.81
Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study. PLoS One (2013) 0.80
Statin-Conferred Enhanced Cellular Resistance against Bacterial Pore-Forming Toxins in Airway Epithelial Cells. Am J Respir Cell Mol Biol (2015) 0.79
Chemical and protein structural basis for biological crosstalk between PPARα and COX enzymes. J Comput Aided Mol Des (2014) 0.79
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol (2004) 0.79
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol? Pharmacogenomics (2010) 0.79
Co-medication of statins with contraindicated drugs. PLoS One (2015) 0.78
CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br J Clin Pharmacol (2012) 0.78
Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.77
Uremic toxins enhance statin-induced cytotoxicity in differentiated human rhabdomyosarcoma cells. Toxins (Basel) (2014) 0.76
Pediatric Statin Administration: Navigating a Frontier with Limited Data. J Pediatr Pharmacol Ther (2016) 0.75
Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. Ther Adv Drug Saf (2012) 0.75
Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (1998) 2.09
Comparison of activated charcoal and ipecac syrup in prevention of drug absorption. Eur J Clin Pharmacol (1983) 2.09
Should the cement mantle around the femoral component be thick or thin? J Bone Joint Surg Br (2003) 2.05
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 2.01
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther (1998) 1.99
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2007) 1.96
Clinical pharmacokinetics of oral activated charcoal in acute intoxications. Clin Pharmacokinet (1983) 1.89
Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol (1979) 1.82
Genomic analysis of the Hsp70 superfamily in Arabidopsis thaliana. Cell Stress Chaperones (2001) 1.73
Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet (1993) 1.70
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther (2009) 1.67
Effect of diuretic, beta-adrenoceptor blocking agent and their combination on elevated blood pressure and serum potassium: a cross-over study. Br J Clin Pharmacol (1978) 1.62
Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther (1997) 1.59
Haemodynamic and catecholamine responses to induction of anaesthesia and tracheal intubation: comparison between propofol and thiopentone. Br J Anaesth (1993) 1.54
Local infiltration analgesia with levobupivacaine compared with intrathecal morphine in total hip arthroplasty patients. Acta Anaesthesiol Scand (2012) 1.53
Acute oxalate nephropathy after ingestion of star fruit. Am J Kidney Dis (2001) 1.51
Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. Int J Clin Pharmacol Ther Toxicol (1985) 1.50
Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther (1998) 1.49
Histopathological study of Sauropus androgynus-associated constrictive bronchiolitis obliterans: a new cause of constrictive bronchiolitis obliterans. Am J Surg Pathol (1997) 1.48
A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther (1993) 1.45
Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther (1998) 1.42
Cyclosporine A increases plasma concentrations and effects of repaglinide. Am J Transplant (2006) 1.40
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther (2001) 1.40
Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther (1996) 1.39
Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol (1980) 1.38
Observation of an antimatter hypernucleus. Science (2010) 1.38
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2009) 1.38
The incidence of active tuberculosis in a large urban area. Am J Epidemiol (1989) 1.35
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther (1999) 1.34
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol (1998) 1.33
Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther (1991) 1.32
The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg (1996) 1.31
Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 1.30
Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. Eur J Clin Pharmacol (1978) 1.29
Interactions with the absorption of tetracyclines. Drugs (1976) 1.29
Sotalol and prolonged Q-Tc interval. Lancet (1981) 1.27
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia (2003) 1.27
Interference of iron with the absorption of tetracyclines in man. Br Med J (1970) 1.25
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol (1998) 1.24
Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology (2007) 1.22
Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol (2002) 1.22
Bioavailability and central side effects of different carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol (1985) 1.22
Prolongation of the Q-T interval caused by sotalol--possible association with ventricular tachyarrhythmias. Eur Heart J (1981) 1.20
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther (2001) 1.19
Drug-related deaths in a university central hospital. Eur J Clin Pharmacol (2002) 1.18
The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG (2000) 1.17
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther (2007) 1.16
Itraconazole decreases renal clearance of digoxin. Ther Drug Monit (1997) 1.16
Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis (1997) 1.15
Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther (1998) 1.13
Biodegradation and biocompatability of a calcium sulphate-hydroxyapatite bone substitute. J Bone Joint Surg Br (2004) 1.12
Inhibitory effect of various iron salts on the absorption of tetracycline in man. Eur J Clin Pharmacol (1974) 1.11
Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol (1994) 1.11
Ocular manifestations of tuberculosis. Ophthalmology (2001) 1.10
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol (2001) 1.08
Infection of the fetus with hepatitis B e antigen via the placenta. Lancet (2000) 1.06
Comment on 'Temperature dependent optical properties of PbS nanocrystals'. Nanotechnology (2013) 1.06
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia (2003) 1.06
An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis (1996) 1.05
Intrarenal mixed germ cell tumor. J Urol (2000) 1.05
Sotalol intoxication with prolonged Q-T interval and severe tachyarrhythmias. Br Med J (1979) 1.05
Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother (2001) 1.05
Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol (1981) 1.05
Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother (1992) 1.04
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos (2001) 1.04
Stereospecificity in some central and circulatory effects of phenylisopropyl-adenosine (PIA). Arzneimittelforschung (1975) 1.04
Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos (2000) 1.04
Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther (2000) 1.04
Antipyretic analgesics in patients on antiepileptic drug therapy. Eur J Clin Pharmacol (1979) 1.03
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (2000) 1.03
Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus (2010) 1.02
Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. Aliment Pharmacol Ther (2006) 1.02
Studies on capillarization of the hepatic sinusoids in alcoholic liver disease. Alcohol Alcohol Suppl (1993) 1.01
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther (2001) 1.00
The clinical significance of food-drug interactions: a review. Med J Aust (1989) 1.00
Milk and yoghurt do not impair the absorption of ofloxacin. Br J Clin Pharmacol (1992) 1.00
Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther (1995) 0.99
Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol (1997) 0.99
Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver. Eur J Clin Pharmacol (1980) 0.99
Effect of zinc sulphate on the absorption of tetracycline and doxycycline in man. Eur J Clin Pharmacol (1975) 0.98
Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol (2003) 0.98
Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther (1998) 0.98
Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease. Gastroenterology (1994) 0.98